Evommune, Inc. (EVMN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Evommune, Inc. (EVMN) Healthcare & Pipeline Overview

Evommune, Inc. is a clinical-stage biotechnology company specializing in therapies for chronic inflammatory diseases. With a focus on innovative treatments like EVO756 and EVO301, Evommune targets conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis, positioning itself within the competitive biotechnology landscape.

What Is the Investment Thesis for EVMN?

Evommune, Inc. presents a focused investment opportunity within the biotechnology sector, targeting chronic inflammatory diseases. The company's pipeline, featuring EVO756 and EVO301, addresses significant unmet needs in conditions like chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. With a market capitalization of $492M, Evommune operates with a high gross margin of 86.4%, indicating strong potential profitability upon successful commercialization. Key growth catalysts include the progression of EVO756 and EVO301 through clinical trials, with potential data readouts in the next 12-24 months. However, the company's negative profit margin of -759.9% reflects its current stage of heavy R&D investment. A beta of 2.31 suggests high volatility, making it suitable for investors with a higher risk tolerance.

Based on FMP financials and quantitative analysis

EVMN Key Highlights

Market Cap of $492M reflects investor valuation of Evommune's pipeline and potential.

• Gross Margin of 86.4% indicates strong potential profitability upon successful commercialization of its therapies.
• Profit Margin of -759.9% highlights the company's current focus on R&D and clinical trials, typical for a clinical-stage biotech.
• Beta of 2.31 suggests higher volatility compared to the market, reflecting the inherent risks in biotechnology investments.
• Focus on chronic inflammatory diseases addresses a large and growing market with significant unmet medical needs.

Who Are EVMN's Competitors?

EVMN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EVMN's Key Strengths?

Focus on a specific therapeutic area (chronic inflammatory diseases).

• Proprietary drug candidates (EVO756 and EVO301).
• Experienced management team.
• High gross margin (86.4%).

What Are EVMN's Weaknesses?

Clinical-stage company with no approved products.

• Negative profit margin (-759.9%).
• High beta (2.31) indicating high volatility.
• Reliance on successful clinical trial outcomes.

What Could Drive EVMN Stock Higher?

EVMN catalyst: Phase 2 trial results for EVO756 in chronic spontaneous urticaria (CSU) expected in Q4 2026.

• Phase 2 trial results for EVO756 in atopic dermatitis (AD) expected in H1 2027.
• Enrollment and progression of patients in clinical trials for EVO301 in ulcerative colitis (UC).
• Potential for strategic partnerships or licensing agreements with larger pharmaceutical companies.

What Are the Key Risks for EVMN?

Clinical trial failures for EVO756 or EVO301.

• Regulatory delays or rejection of drug candidates.
• Competition from established pharmaceutical companies with greater resources.
• Patent challenges or intellectual property disputes.
• Difficulty in raising additional capital to fund ongoing research and development.

What Are the Growth Opportunities for EVMN?

• Advancement of EVO756 for Chronic Spontaneous Urticaria (CSU): EVO756 targets CSU, a condition with limited effective treatments. Positive Phase 2 trial results could lead to accelerated development and potential FDA approval. The CSU market is projected to reach $4.5 billion by 2028, offering a substantial revenue opportunity for Evommune. Successful commercialization would establish Evommune as a key player in the CSU treatment landscape.
• Expansion of EVO756 into Atopic Dermatitis (AD): EVO756 is also being developed for atopic dermatitis, a chronic skin condition affecting millions. The AD market is estimated to reach $12 billion by 2027. Positive clinical trial data could position EVO756 as a competitive alternative to existing treatments, driving significant revenue growth for Evommune. This expansion leverages the same drug candidate for multiple indications, enhancing efficiency and potential return on investment.
• Development of EVO301 for Ulcerative Colitis (UC): EVO301 targets ulcerative colitis, a chronic inflammatory bowel disease. The UC market is projected to reach $7.5 billion by 2028. Successful clinical trials and regulatory approval could establish EVO301 as a valuable treatment option, contributing significantly to Evommune's revenue. This represents a strategic diversification into gastrointestinal diseases, broadening the company's therapeutic focus.
• Strategic Partnerships and Licensing Agreements: Evommune can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its therapies. Licensing agreements could provide upfront payments, milestone payments, and royalties, generating significant revenue streams. These partnerships would also provide access to established infrastructure and market expertise, enhancing Evommune's ability to reach patients globally.
• Expansion into New Therapeutic Areas: Evommune can leverage its expertise in chronic inflammatory diseases to expand into new therapeutic areas, such as rheumatoid arthritis, psoriasis, and Crohn's disease. These conditions represent significant market opportunities and align with Evommune's core competencies. This diversification would reduce the company's reliance on its current pipeline and create new avenues for growth.

What Are EVMN's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Expertise in developing therapies for chronic inflammatory diseases.
• Clinical trial data demonstrating safety and efficacy.
• Potential for strategic partnerships with larger pharmaceutical companies.

What Does EVMN Do?

Evommune, Inc., founded in 2020 and based in Palo Alto, California, is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapies for chronic inflammatory diseases. The company's mission is to address unmet medical needs by targeting key drivers of these diseases. Evommune's initial clinical development programs are centered on chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC), conditions that affect millions worldwide and often have limited treatment options. The company's lead product candidates include EVO756, which is being developed for the treatment of CSU and AD, and EVO301, which is being developed for the treatment of AD and UC. These therapies are designed to modulate the immune system and reduce inflammation, thereby alleviating the symptoms and improving the quality of life for patients suffering from these chronic conditions. Evommune operates primarily in the United States, focusing on research, development, and clinical trials to advance its pipeline. The company's strategy involves identifying promising therapeutic targets, developing innovative drug candidates, and conducting rigorous clinical testing to demonstrate safety and efficacy. Evommune aims to partner with larger pharmaceutical companies to commercialize its products globally, leveraging their established infrastructure and market access.

What Products and Services Does EVMN Offer?

• Develop therapies for chronic inflammatory diseases.
• Focus on conditions like chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Target key drivers of inflammatory diseases to develop innovative treatments.
• Advance EVO756 for the treatment of CSU and AD.
• Advance EVO301 for the treatment of AD and UC.

How Does EVMN Make Money?

• Develop and patent novel therapeutic compounds.
• Conduct preclinical and clinical research to demonstrate safety and efficacy.
• Seek regulatory approval from the FDA and other agencies.
• Potentially partner with larger pharmaceutical companies for commercialization.

What Industry Does EVMN Operate In?

Evommune operates in the biotechnology industry, which is characterized by high innovation, intense competition, and significant regulatory oversight. The market for chronic inflammatory disease therapies is substantial and growing, driven by an aging population and increasing prevalence of autoimmune disorders. Key trends include the development of targeted therapies, personalized medicine, and the use of biomarkers to improve treatment outcomes. Evommune competes with both established pharmaceutical companies and other emerging biotech firms, including Ligand Pharmaceuticals Incorporated (LGND), all vying for market share in this lucrative space.

Who Are EVMN's Key Customers?

• Patients suffering from chronic spontaneous urticaria.
• Patients suffering from atopic dermatitis.
• Patients suffering from ulcerative colitis.
• Healthcare providers who treat these conditions.

Wall Street analysts project Evommune, Inc. revenue of about $4.1M for fiscal 2026, with EPS near $-2.99. The estimate reflects 5 contributing analysts.

Evommune, Inc. has missed Wall Street's EPS estimate in 3 of its last 5 reported quarters — a mixed record worth weighing. Reported results have landed about 170.3% below estimates on average.

Evommune, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 11.15 places it in the safe zone, indicating low near-term bankruptcy risk.

Key Financial Metrics

Return on assets is -23.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -42.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 20.36 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.0%, the inverse of the P/E and a quick read on earnings relative to price.

Evommune, Inc. (EVMN) Valuation Context

Valued at $492M, EVMN is classified as a small-cap stock. Relative to its peer group, EVMN's quantitative score of 24/100 is below the peer average of 89/100.

Company Profile

Evommune, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Palo Alto, US. The company is led by CEO Luis C. Pena. EVMN has traded publicly since 2025.

EVMN Financials

EVMN Latest News

EVMN Analyst Consensus

EVMN MoonshotScore

EVMN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources